Presentation is loading. Please wait.

Presentation is loading. Please wait.

DPRE-DRI 1 Inserm French National Institute of Health and Medical Research Created in 1964 from the National Institute of Hygiene and Hospital Research.

Similar presentations


Presentation on theme: "DPRE-DRI 1 Inserm French National Institute of Health and Medical Research Created in 1964 from the National Institute of Hygiene and Hospital Research."— Presentation transcript:

1 DPRE-DRI 1 Inserm French National Institute of Health and Medical Research Created in 1964 from the National Institute of Hygiene and Hospital Research Working through the Ministries for Research and Health

2 DPRE-DRI 2 Inserm : key figures Budget 2006 : 700 M Total staff: (2 500 physicians) of which Inserm employees (62% of total budget dedicated to salaries) 335 Inserm laboratories 19 research centers 374 French and foreign firms are partners of Inserm An active patent portfolio of 572 families 41 Clinical Investigation Centers (CIC) 56 start-up companies based on Inserm technology

3 DPRE-DRI 3 What is Inserm ? The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health All fields of research are covered in these domains 80% of the 354 research units are located in University hospitals Research units with 8 years mandate with mid-term (4 year) evaluation. Stringent evaluation Investigator- driven projects - AVENIR programme Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.

4 DPRE-DRI 4

5 5 Inserms share (%) of publications in France Publications

6 DPRE-DRI 6

7 7 Inserm publishing visibility ( ) Number of citations % publications

8 DPRE-DRI 8 Inserm Affiliations

9 DPRE-DRI 9 Field Evolution (publications 1995 – 2005)

10 DPRE-DRI 10 Evolution of the clinical medicine field (publications 1995 – 2005)

11 DPRE-DRI 11 New England Journal of Medicine (IF=44,016), JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878) Science (IF=30,927) and Nature (IF=29,273)

12 DPRE-DRI 12 The Inserm performance bibliometric analyses

13 DPRE-DRI 13

14 DPRE-DRI 14

15 DPRE-DRI 15 New England Journal of Medicine (IF=44,016), JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878) Science (IF=30,927) and Nature (IF=29,273)

16 DPRE-DRI 16 Organization Bottom-up initiatives: selection based on quality and innovation Bottom-up initiatives: selection based on quality and innovation Networks focused on major public health issues Networks focused on major public health issues

17 DPRE-DRI 17 Bone and Joint Diseases 2.2% Diabetes 2.6% Hepatitis 3.1% Genetic diseases 10.5% 16.8% Cancer Cardiovascular diseases 9.1% 17.1% Immunology of which 9.3% for neurologic disorders 20.6% Neurosciences Infectious diseases and microbiology (without Aids and Hepatitis) 8.3% Public health 7.5% Handicap 5.1% Nutrition 4.8% AIDS 3.7% Research laboratories being often involved in more that one domain, the overall distribution is over 100 %

18 DPRE-DRI 18 Inter-research agencies programmes : - CNRS : SPI, STIC, chemistry, etc.. - INRIA Dedicated research units in specific infrastructures: ex: CNG, Nanotechnology Dedicated research Programmes : - Nanotechnology - « Systems biology » Training « Interdisciplinarity »

19 DPRE-DRI 19 Inserm : creation of research centers Objectives and main characteristics: Critical mass (100 to 300 staffs), Mutualisation and Integration International visibility, Attractiveness Assessment criteria: Scientific excellence Quality of the management : Governing structure, mutualised administration & management Technology transfert and research outcomes Sharing of technical facitilies Coordination of scientific events and programmes Implementation of research training programmes International scientific council for evaluation of scientific strategy (turn- over of scientific teams : mobility, hosting new scientists or teams,…)

20 DPRE-DRI Centres de Recherche au 1/07/2007

21 DPRE-DRI Research Centers in 2007 Some exemples: 1- Paris 6, Pluri-thematic 2- Paris 6, Neurophysiology 4- Paris 5, Pluri-thematic 5- Créteil, Pluri-thematic 6- Lilles, Pluri-thematic 7- Dijon, Cancer/Nutrition 8- Bordeaux, Neurophysiology 9- Grenoble, Neurophysiology 10- Grenoble, Cancer 11- Toulouse, Pluri-thematic

22 DPRE-DRI 22 Evolution des unités et CDR entre 2001 et 2007

23 DPRE-DRI 23 Infrastructures de recherche CNRG: CNS, CNG, RNG R.I.O: Inserm, CNRS, CEA, INRA (Universités, Hôpitaux) IFR Régions Unités De recherche EUROPE 7e PCRDT ESFRI « Grosses » infrastructures: P4 (Lyon) ICS (Strasbourg) Mircen (Fontenay: CEA-Inserm)

24 DPRE-DRI 24 Research infrastructures National Genomic Research Consortium: CNRG National Sequencing Center National Genotyping Center Regional Genopoles Core Facilities Biosafety-level 4 laboratory Local and regional technological plateforms Clinical Research Infrastructures

25 DPRE-DRI 25 Regional clusters 1.Canceropoles, other thematic poles (Neuropole, …) 2.Competitivityclusters 2.Competitivity clusters (Industry) 3.Regional poles for research in Neurosciences, etc.

26 DPRE-DRI 26 Competitivity Clusters 67 created clusters 7 involving Inserm units International National Emergent Virology Nutrition, Ageing Imaging, Cancer, Biotherapies, Neurosciences Biotherapies Cancer, therapeutics Therapeutic innovation Nutrition

27 DPRE-DRI 27 National infrastructures : Regional infrastructures : Animal experiments Functional investigations Transcriptomics Proteomics In vivo imaging Structural biology Cellular imaging Sequencing Electron microscopy Lille Rouen Caen Paris Nancy Strasbourg Rennes Orléans Dijon Nantes Lyon Bordeaux Grenoble Clermont- Ferrand Poitiers Nice Toulouse Marseille Montpellier Rousset National & 23 Regional infrastructures

28 DPRE-DRI 28 Main Inserms priorities 1.« Researchers » : Careers, Training & Mobility 2.To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach 3.To establish Inserm in a European and International context 4.To develop public/private partnerships

29 DPRE-DRI 29 Researchers : Career, Training and Mobility

30 DPRE-DRI 30 NEW CAREER TRACKS To strengthen the status of young scientists; to recognize, evaluate and promote scientific qualities: high level fixed term contracts and the program AVENIR To offer tenure positions to researchers: mid and long-term research plans To increase research career development and mobility and foster partnerships: INTERFACE RESEARCH GRANTS General principles

31 DPRE-DRI 31 Le recrutement chercheur Contrats jeunes chercheurs « Juniors »: 5 ans (évaluation intermédiaire à 3 ans) 30%: Avenir Suivi: mission chercheurs Chargés et Directeurs de recherche Contrats post-doctorants 12 mois (24 mois ?) (Postes verts)

32 DPRE-DRI 32 Post-doctoral career track Inserm-NIH (appel doffres permanent) Candidats proposés par lInserm après leur thèse: 3 ans de post-doctorat dans lun des instituts des NIH « intra-muros ». Suivi personalisé (mission chercheurs), évaluation de la qualité du stage post-doctoral Contrat Junior (5ans, avec évaluation à 3 ans) Contrat temporaire universitaire ou HU Recrutement: EPST, Université etc..

33 DPRE-DRI 33 Contrats dinterface pour chercheurs et ingénieurs de recherche CR DR IR Hôpital CHU, CLCC 383 Internationaux (Labos internationaux) 2 Agences Sanitaires N: 5 Inserm (ISFIC) Chercheurs: 50 Ingénieurs: 37 Université 60 Industrie 6

34 DPRE-DRI 34 Contrats dInterface Médecins hospitaliers et HU et Enseignants- chercheurs HOPITALINSERM 88 PH, MCU-PH, PU-PH UNIVERSITEINSERM 11 enseignants-chercheurs

35 DPRE-DRI 35 Career tracks in Inserm Junior, temporary (5years with 3year intermediate evaluation), high level contracts Avenir program European programs: EURYI, ERC Permanent positions for senior scientists

36 DPRE-DRI 36 AVENIR Programme Eligibility: Young scientists with permanent or temporary position, clinicians Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities Each successful candidate is allocated: A yearly budget of 60 K euros Minimum lab space of 50 m2 Personnel: 1 post-graduate collaborator and 1 graduate student Each successful young scientist receives a salary for 5 years

37 DPRE-DRI 37 Tenure career track: General principles Design tenure career tracks with reasonable security: Academic freedom Reinforce interface with partners: intersectoral mobility: - Hospitals: clinical research, health policy issues - Health agencies - Universities: teaching, making scientific information available to the society - Industry: technological transfer and valorisation European mobility ?

38 DPRE-DRI 38 Interface contracts : General principles Based on : a permanent position + temporary, 3-5 year contracts To reinforce interactions with partners and mobility -Hospitals: clinical research, medical issues -Health agencies: health policy issues -Universities: teaching, making scientific information available to the society Industry: technological transfer and valorisation European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)

39 DPRE-DRI 39 CR DR Universities DGS / Health agencies International (Hospitals, universities) New Career Track Tenure position year contracts: " 2/3 – 1/3 " University hospitals Cancer centers Industry Inserm

40 DPRE-DRI 40 David SASSOON Born on May 25, 1959 Presently : Professor of Molecular Biology, Mount Sinai Medical School, New York, USA Joint Inserm/AFM/Paris VI operation Research theme: muscle development DR1 permanent position + interphase contract (AP-HP) Inserm Unit Chair of excellence 2004 (MR), Avenir Laboratory space: 750 m2: Pitié-Salpêtrière hospital Accompagnying measures: - IR Paris VI - Temporary contracts -Assistance with school, housing…

41 DPRE-DRI 41 Thomas BAUMERT, M.D. Born on May Presently: Assistant professor, Dept of Medicine University of Freiburg, Germany Inserm/ULP/HUS Strasbourg joint operation Research theme: HCV Laboratory: Virology laboratory in Strasbourg DR2 permanent position + Interphase contract HUS Inserm unit, Avenir: in progress Temporary contracts Assistance with school, housing… PU-PH

42 DPRE-DRI 42 Matthew ALBERT, M.D. PhD Born on December 9, 1970 Was: Clinical Scholar, Rockfeller University and Resident Clinical Pathology The New York Hospital New York, USA Inserm/Pasteur Institute/Necker Hospital joint operation Research theme: Dendritic cell biology/HCV/Cancer Location: Pasteur Institute Paris Since June 2003 : Inserm DR2 permanent position + Interphase contract AP-HP + Team Leader Pasteur Institute Inserm Avenir Unit and Pasteur Institute Unit Temporary contracts (junior scientists, MDs) Assistance with housing

43 DPRE-DRI 43 Inserm : key figures Budget 2006 : 700 M Total staff: (2 500 physicians) of which Inserm employees (62% of total budget dedicated to salaries) 325 Inserm laboratories 19 research centers 374 French and foreign firms are partners of Inserm An active patent portfolio of 572 families 41 Clinical Investigation Centers (CIC) 56 start-up companies based on Inserm technology

44 DPRE-DRI 44 Interface Contract grants for MDs Reinforce research activities of clinicians and university research assistants and professors 3-5 year contracts for clinicians : assistant professors and professors, university employees Grant paid by Inserm to hospitals and universities to be used for : - clinical and teaching activities: temporary positions - financing research activities

45 DPRE-DRI 45 The School of Inserm A 3 year Educational programme which leads to a Master and MD-PhD track First year of Inserm School - Second year of Medical School : Special School Intensive Training Session in February June: Competitive Exam Second year of Inserm School - Third year of Medical School 6 month full time Research Clerkship in an Inserm Research Laboratory Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree

46 DPRE-DRI 46 Clinical research and Translational research strategy

47 DPRE-DRI 47 To develop dedicated performing Research Infrastructures To sponsor clinical studies and innovative therapeutic clinical trials To ensure appropriate training of Physicians to Research skills and vice-versa To integrate these actions in a European context: ECRIN, Biological resource centers: Roadmap ESFRI Innovative medecine platform A continuum from Basic to Clinical Research: Translational research

48 DPRE-DRI 48 Basic Research Preclinical studies : Proof of concept Inserm [CRC] Inserm Phases IIb-III Phase IV Cohorts Clinical trials Clinical trials Proof of concept Phases I-IIa Biotherapy

49 DPRE-DRI 49 The new challenges of clinical research in Europe To support development of new therapeutic molecules : Innovative BASIC research approaches Innovative CLINICAL research: therapeutic and physio-pathological studies in between : dedicated research infrastructures To support Innovation and Biotechnology sector development To satisfy end-users (patients) requirements

50 DPRE-DRI 50 Inserm, as a major actor of the Clinical Research in France and in Europe To set-up an efficient Translational research towards the benefits of patients To develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI) To sponsor clinical studies and innovative therapeutic clinical trials To ensure appropriate training of Physicians to Research skills and vice-versa : School of Inserm To built a continuum from Basic research to Clinical Research

51 DPRE-DRI 51 Clinical research infrastructures Clinical research centers Tissues Banks Cohorts Registries Networks 22 9

52 DPRE-DRI < CIC CIC-EC CIC Biothérapie Collections biologiques Cohortes Registres Réseaux Infrastructures de recherche clinique Et en santé des populations Infrastructures de recherche clinique Et en santé des populations 35

53 DPRE-DRI 53 Les CIC CIC « généralistes » CIC-EC: épidémiologie et gestion des essais cliniques CIC-Biothérapie 2007: CIC-»innovations technologiques »

54 DPRE-DRI 54 CIC et Unités Inserm Promotions Inserm: 20% demandées par les CIC Etudes et essais cliniques réalisées dans les CIC: environ 20-30% viennent des unités

55 DPRE-DRI 55 CIC Services de soins et de biologie CHU Postes daccueil pour internes Contrats chercheurs Juniors 5 ans Contrats dinterface Unités de recherche Inserm Equipes de recherche Translationnelle Budget de base + projets Comment renforcer les collaborations?

56 DPRE-DRI 56 Bichat Henri Mondor (94 Créteil) Pitié- Salpêtrière Necker Enfants Malades Robert Debré Saint-Louis Saint- Antoine HEGP Les Cochin IGR (Villejuif) CIC, CIC-BT and CIC-EC (2006) Saint-Pierre Ile de la Réunion CIC (23) CIC-EC (7) CIC-BT (11) Lille Rennes Nantes Tours Nancy Strasbourg Lyon Montpellier Marseille Bordeaux Toulouse Grenoble Rouen Saint-Etienne Dijon Brest Clermont-Ferrand Besançon

57 DPRE-DRI 57 Key Figures of the Clinical Research 797 on-going Clinical trials monocentrics French multicentrics European and international multicentrics About patients expected to be included and currently involved 120 beds devoted to clinical trials A staff of professionals 101 physicians, pharmacists, 27 biostatisticians, psychologists, researchers 69 nurses 51 Clinical research technicians, administrative

58 DPRE-DRI 58 Thematic networks of CIC Cardiovascular : 14 CIC Coordinator : F. Zannad, CIC de Nancy Metabolic diseases and diabetes : 9 CIC Coordinator : P. Petit, CIC de Montpellier Gastro-Enterology-Hepatology : 9 CIC Coordinator : C. Libersa, CIC de Lille Thrombosis : 3 CIC Coordinator : H. Decousu, CIC de St Etienne Cancer Coordinator : F. Calvo, CIC de St Louis (AO-HP) Neurosciences : 13 CIC Coordinator : Ph. Damier, CIC de Nantes Paediatric : 8 CIC Coordinator : E. Jacqz-Aigrain, CIC Robert Debré de Paris

59 DPRE-DRI 59 Pan-European network of Clinical research infrastructures: the ECRIN network of INSERM ECRIN : European Clinical Research Infrastructures Network France CIC & UEC Spain SCReN Italy CIRM & IRFMN Germany KKS Denmark DCRIN Sweden SweCRIN Québec FRSQ-GEREQ Other networks National networks of Clinical Research Centres Clinical Trial Units EFGCP ECRIN should be considered as a tool that will allow: - to access research facilities certified as compliant with the GMP/GLP standards in Europe - to access expertise in the preparation and conduct of trans- national clinical trials - to access scientific and ethic evaluations

60 DPRE-DRI 60 ECRIN : a Platform of Integrated services to multinational studies Integrated services (one-stop shop) to multinational studies: 1 - interaction with ethics commitees 2 - interaction with competent authorities, regulatory affairs 3 - drug dispensing 4 - adverse event reporting 5 - data management 6 - study monitoring 7 - management of biological samples

61 DPRE-DRI 61 Biological Resources Centres a networking action at both National and European Levels

62 DPRE-DRI 62 Lille Caen Rennes Nantes Tours Nancy Strasbourg Lyon Montpellier Marseille Dijon 1 Grenoble 2 Toulouse 2 Amiens 1 1 Angers Brest 1 2 Reims 36 IDF BRCs in France BRCs in France National policy of the Ministry for Research and the National Research Agency to support the development of BRCs

63 DPRE-DRI 63 Key components to: Industry : external sourcing: innovative targets, hits and leads, biomarkers, clinical studies… Academic : valorisation, technology tranfer and dissemination of knowledge. Biological Resources Centres

64 DPRE-DRI 64 "Service providers and repositories of the living cells, genomes of organisms, and information relating to heredity and the functions of biological systems" (O.E.C.D. definition). Infrastructures that qualify biological samples (DNA, RNA, proteins…), provide samples for national projects and keep samples for the future (inheritage). Biological Resources Centres

65 DPRE-DRI 65 The necessity of a European network : To co-ordinate European scientific programs and policies : 7 th PCRD To develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials. Valorisation of knowledge Attractiveness of public research and development of innovative SMEs. European Biological Resources network (EBRC)

66 DPRE-DRI 66 The European BRCs brings together: Service and work facilities made up of collections that satisfy the EU research objectives Conservation sites made up of patrimonial reference collections : national collections, cryobanks, rare tissue or tumour collections… Ongoing European initiatives : Contact at Inserm :

67 DPRE-DRI 67 From Cohorts to Biomarkers Cohorts : key issues for Inserm Access to "thematic" cohorts of patients (cancer, mental diseases, etc.) Access to cohorts of healthy volunteers for prospective studies, genetic studies, etc. The Challenges of Biomarkers Clinic : prediction, diagnostic and prognosis Bio-pharmaceutical industry : Valorisation of Research in partnership with industry.

68 DPRE-DRI 68 Platforms for GMP production State of the art : Platforms for production of therapeutic vectors : Nantes (Atlantic biothérapies), Généthon, etc. Platforms for production of bio-medicines : LFB, Genopole Ile-de-France, Vivalis, Lipidomix, etc. Platforms for production of therapeutic virus : Heidelberg Perspectives : availability of GMP products Partnership with Inserm-Transfert Costs sharing European dimension : ESFRI / IMI

69 DPRE-DRI 69 IMI : Innovative Medicines for Europe European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way. Inserm is the French representative in the Member states contact Group of IMI

70 DPRE-DRI 70 Organization Bottom-up initiatives: selection based on quality and innovation Bottom-up initiatives: selection based on quality and innovation Networks focused on major public health issues Networks focused on major public health issues

71 DPRE-DRI 71 National Research Programs To bring together all parties interested in a given research area: Research institutes Universities Hospitals Sanitary Agencies Charities and Foundations Medical Societies Social protection agencies Patient Associations Industry To launch calls for proposals open to the scientific community regardless of institutional affiliation To support young investigators, scientists and clinicians

72 DPRE-DRI 72 National Research Programmes Main missions of the Inserm National Research Programmes : To support new/young research teams To support organisation of seminars and workshops : prospective studies and follow-up of actions To identify projects that could be submitted to FP7 or some other international programmes (NIH, etc Collaborations with the NIH: seminars and grants To reinforce partnerships with Patients associations Medical specialised scientific societies Industry

73 DPRE-DRI 73 National Research Programmes National Research Program on Cardiovacular Diseases PNRC National Research Program on Diabetes PNRD in collaboration with CNRS National Research Program on Human NutritionPRNH in collaboration with INRA National Research Program on Bone and Joint DiseasesPRO-A Virtual Institute for Public Health Research IVRSP National Research Program on sense organsPNRV

74 DPRE-DRI 74 ProjectsANR,INCAANRS…..ProjectsANR,INCAANRS….. National Research ProgramsNetworks ProgramsNetworks PNRD PNRC PRNH ATC BIOTHERAPY ATC DRUGS SYSTEMS BIOLOGY ATC ALCOHOL PRO-A IVRSP PNR-Dermato PNR-O. Sens PNR-Hépato-GE PNR-Endo-Repro EUROPE NIH Missions: - Recruitments: Avenir etc. - Research structures: centres - Projects: cohorts etc..

75 DPRE-DRI 75 National Research Agency (ANR) Created in February 2005 with a total yearly budget: around 800 M (approx. 25 % dedicated to Biomedical sciences) Main objectives : support to basic research projects support to translational research (partnerships) Launched calls for thematic and "free" programmes : Cardiovascular diseases, Obesity, Diabetes Neurosciences, psychiatry Microbiology- Immunology Rare diseases Projects of scientific excellence : 370 k for a 3-year duration and involving 3 to 4 partners (in average)

76 DPRE-DRI 76 National Research Agency (ANR) Main figures in 2005: 35 calls for proposals published 5652 proposals submitted Success rate : 25,7% => 1454 projects / 4500 research teams Breakdown of budget available / scientific domains : 30% Non-thematic 25% Matter and Information 19% Biology and Health 18% Sustainable energy and environment 8,8% Ecosystems and sustainable development Specific actions and support to Partnership & Competitiveness, Young researchers (including chairs of excellence)

77 DPRE-DRI 77 Inserm - ANR ProgramManagement Inserm - ANR Programme Management Launch of the Thematic programme "Biology and Health" In 2005 Cardiovascular, Obesity, Diabetes Neurosciences, neurology and psychiatry Microbiology - Immunology Rare diseases Health and environment Health technologies Emerging and maturation of biotechnology projects In 2006 Physio-pathology of human diseases Neurosciences, neurology and psychiatry Microbiology- Immunology- Emerging diseases Rare diseases Research and Innvovation in Biotechnology Emerging and maturation of biotechnology projects Biological Resources sampling in Health

78 DPRE-DRI 78

79 DPRE-DRI 79 The European and International cooperations

80 DPRE-DRI 80 The European policy of Inserm

81 DPRE-DRI 81 The main axes EU Prospectives (ESF, EUROHORCS, etc.) Participation in European programmes : RTD FP & Public Health FP Infrastructures - ESFRI (ECRIN, …) Researchers mobility within EU programmes and Bilateral actions: Common Research projects - Associated laboratories - Joint-units abroad

82 DPRE-DRI 82 Multilateral cooperation actions Participation to the European Research and Public health programmes Inserm and The 6th Framework Programme of the EU Inserm and The 7th Framework Programme of the EU ( )

83 DPRE-DRI 83 CANCER 7 inter-regionalCanceropoles

84 DPRE-DRI 84 Inserm-Transfert SA Private subsidiary of the French National Institute for Health and Medical Research (Inserm) Created by Inserm in 2001, funded up to 4,5 M by Inserm and comprising actually 50 people Increase researchers awareness of technology transfer and company creation Identification and promotion of innovative projects emerging from Inserms laboratories Launch of a new seed fund called Inserm-Transfert Initiative with three major investors in the biotech field (Sofinnova, Ventech, CDC Entreprise) - Capital amount = 4.2 M

85 DPRE-DRI 85 International project management 21 projects under management (6 Network of Excellence, 3 Integrated Projects, 12 STREP) and 8 projects under negociation Total budget for all projects under management over 200 million Creation of value by up-coming licensing and SMEs participation Inserm-Transfert has invested 800 kEuros in 11 new biotech companies that have raised 85 million euros 600 patents' family - 60 to 90 New demands/year licensing agreements Biotech start-up creation and Patenting

86 DPRE-DRI 86 Bilateral cooperations actions Researchers' mobility (short-medium term, Interface Contract grants) Research networks ( EU programmes, NIH, Bill Gates etc..) Associated laboratories Joint Research unit abroad

87 DPRE-DRI 87 Bilateral cooperations actions Researchers' mobility (short-medium term, Interface Contract grants) European research networks at the bilateral level and within the EU programmes European Associated laboratories Joint Research unit abroad

88 DPRE-DRI 88 Cooperations between Inserm and German Partners (1) One formal agreement with DFG : short-term exchange of researchers based on 2 years projects 538 cooperation undertaken since 1985 Main city: Berlin, Bonn, Munich, Freiburg, Heidelberg Main thematic areas : Cellular Biology,Neurosciences, Immunology, Cancer, Genomics, Cardiovascular diseases,… 51 German Post-doc, Researchers and Fellows in the Inserm's research units in 2005 Cooperation with Freiburg: 35 projects, mainly in dermatology, neurosciences, virology, toxicology, etc

89 DPRE-DRI 89 Cooperations between Inserm and German Partners (2) Associated laboratories under preparation (HEGP/La Charité - Freiburg/Strasbourg) A Joint Unit Abroad - U701 Inserm / DKFZ (J. Rommelaere - Heidelberg) - Cancer and Virotherapy In the frame of the 6th EU Framework programme : 59 European research projects mainly in the LSH priority : 16 NoE - 27 IP - 14 STREPs - 2 CA (84 Inserm's teams - 83 German teams Future collaborations within the FP7 : Health priority, IMI, Infrastructures (ECRIN, BRCs)

90 DPRE-DRI 90 Cooperations between Inserm and Hungarian Partners (1) cooperation projects undertaken since 1985 => more than 61 common publications Main cities: Budapest, Szeged, Debrecen Main Partner Institutions : Hungarian Academy of Sciences, Semmelweis University, University of Debrecen etc. Main thematic areas : Neurosciences, Cellular Biology, Molecular Biology, Cardiovascular Physiopathology, Biochemistry… 10 Hungarian Post-docs, Researchers and Fellows within Inserm's research units in 2005

91 DPRE-DRI 91 In the frame of the 6th EU Framework programme : 13 European research projects mainly in the LSH priority : 5 NoEs - 7 IPs - 1 STREP (17 Inserm's teams Hungarian teams) Future collaborations within the FP7 : Health priority, IMI, Infrastructures (ECRIN, BRCs) 91 Cooperations between Inserm and Hungarian Partners (2)

92 DPRE-DRI 92 Associated Laboratory Inserm Unit Abroad Scientific driven 2x4 years mandate Synergies: competencies and facility access Co-funding by Inserm and Associated partners Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts) Networks, EU research projects Bilateral cooperations tools

93 DPRE-DRI 93 1.European Associated Laboratory 2.Inserm Unit Abroad Scientific driven 2x4 years mandate Synergies: competencies and facility access Co-funding by Inserm and Associated partners Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts) EU research projects - Networks Bilateral cooperations tools

94 DPRE-DRI 94 Bruxelles Heidelberg Glasgow Rome Milan Prague European Associated laboratory (LEA) Toulouse : D. Langin U586 / Prague : V. Stich (Univ. Charles) Lille : M. Capron U547 / Bruxelles : M. Goldman (IMI) Associated laboratories (under preparation) Milan / Bordeaux Rome / Villejuif Rome / Nice Ferrara / Paris Dundee / Toulouse Freiburg / Strasbourg Berlin / Paris Barcelona / Paris Porto / Toulouse Joint Research Unit in Europe : Université de Glasgow / C. Doerig U609 DKFZ / J. Rommelaere U701 Dundee Ferrara Berlin Freibur g Barcelona Porto

95 DPRE-DRI 95 Brussels Heidelberg Glasgow Rome Milan Prague Dundee Barcelona Porto London Freiburg Joint Research Unit in Europe: Glasgow University / C. Doerig (Inserm U609) DKFZ / J. Rommelaere (Inserm U701) European Associated Laboratories (LEA) Toulouse Prague: D. Langin (Inserm U586) - V. Stich (Univ. Charles) Lille Brussels: M. Capron (Inserm U547) - M. Goldman (Univ. Libre de Bruxelles) Toulouse Dundee: AC Prats (Inserm U589) - JC Bourdon (Univ. Dundee) Bordeaux Milan: A. Bikfalvi (Inserm E 113) - L. Bello (Univ. Degli Studi) Nice Rome: G. Meneguzzi (Inserm U 634) - G. Zambruno (IDI-IRCCS) Villejuif Paris Sud Rome: D. Samuel (Inserm U 785) - M. Levrero (Univ. La Sapienza) Montpellier London: K. Ritchie (Inserm U 888) - G. Thornicroft (Kings College of London) Strasbourg Freiburg: T. Baumert (Inserm U 748) - H. Blum (Univ. of Freiburg) Villejuif Paris Sud Barcelona: T. Moreau (Inserm U780) - J. Antό (PRBB, IMIM-CREAL) Bordeaux Porto: L. Bordenave (Inserm U 577) - M. Barbosa (IBMC, INEB)

96 DPRE-DRI 96 Montréal Pittsburgh Rio de Janeiro INSERM Unit Associated Laboratory In preparation Irvine Montreal Shanghai Tokyo Kyoto Seoul New York Nanjing Dallas Beijing Haïfa Doha Los Angeles Buenos Aires Laval WuhanRabat Guangzhou Singapour

97 DPRE-DRI 97 « European and International Interface Contract » grants ? Pilot action under preparation Permanent position by Inserm + temporary contract: 2/3 base salary + 1/3 supplementation

98 DPRE-DRI 98 Japan is the first partner of Inserm in Asia (ca. 180 collaborative projects). An increase between 2000 and 2006 (+40%). About 20 Japanese scientists within Inserm units each year. 2% of Inserm publications are with Japan. Long term relationship Inserm- JSPS : 80 projects funded since 1994 Inserm-Japan

99 DPRE-DRI 99 International Associated laboratory with the RIKEN DRI on lipidomics study of membrane microdomains. Inserm Unit in Kyoto University Graduate School of Medicine on trans- ethnic comparative human genomics A clinical research partnership between Inserm and its partners and the Translational Research Center of Kyoto University. A collaborative agreement with the Riken so as to foster our partnership in : Stem cell biology (Riken CDB) Immunology (Riken RCAI) Neurosciences (Riken BSI) Inserm-Japan : New Avenues of Collaborations

100 DPRE-DRI 100 Inserm International Laboratories and Inserm Unit in Japan INSERM Unit Associated Laboratory In preparation Tokyo Kyoto Tokyo

101 DPRE-DRI 101 Evaluation of participation of Inserm to the 6th FP as in March 2006 Inserm is involved in 99 projects (including coordination of 24 projects) Inserm is involved in 99 projects (including coordination of 24 projects)

102 DPRE-DRI 102 Accompanying measures of Inserm Project preparation mainly within the FP6 programme : partnership with Inserm Transfert SA The « Europe Task Force » actions: Information and promotion Pre-evaluation of potentiaI EU projects Coordination / partnership of Inserm S&T, administrative, legal and financial follow-up Follow-up of the next FP7 (Thematic priorities, JTI, …)

103 DPRE-DRI 103 Missions of the European Affairs division of the DPRE Information European project preparation and follow-up, in close collaboration with Inserm-Transfert (the private subsidiary of Inserm) To represent Inserm at Brussels and near other European institutions To follow European policies development and to evaluate opportunities To set-up and coordinate bilateral cooperations

104 DPRE-DRI 104 The European Affairs division A dedicated Team Contact person in each connected/involved Inserm departments: The EUROPE Task Force A permanent staff in Brussels (CLORA) A contact in London A competence centre in Project management within Inserm-Transfert A specific budget

105 DPRE-DRI 105 The « Europe Task Force » of Inserm DRI DRCT - Lobbying - Information - Marie-Curie programme - Training sessions and information targeted to: Administrative staffs Projects' coordinators - Consortium agreements - Preparation & management of EU projects - Costs models - Budgets - Contractual issues - Infrastructures - ERA-NETs - Ethics CLORA DG RESEARCH EC Inserm's Laboratories Inserm Transfert ADRs DFL DRH Europe Innovative Start-up DAPS DPRE Regional & National Partnerships European Partnerships - Clinical research - JTI/IMI END - Bilateral cooperation - LEA/Unit abroad

106 DPRE-DRI 106 Inserm-Transfert as the vector of Inserms Technology Transfer Universities Inserm-Transfert International institutions Pharmaceutical companies Biotech companies Investors/ VCs Inserm

107 DPRE-DRI 107 Inserm-Transfert activities: forwarding science into business Inserm Inserm-Transfert Technology Transfer & Licensing International Projects Management Industrial Projects Management Proof-of-Concept validation Biotech Companies creation Sourcing & IP Management

108 DPRE-DRI 108 Researchers : Career, Training and Mobility

109 DPRE-DRI 109 « European Interface Contract » grants ? Pilot action under preparation with European institutions ( Italy, Portugal, UK, Spain, Germany,..) Permanent position by Inserm + temporary contract: 2/3 base salary + 1/3 supplementation Co-funding strategy : one of the European Marie Curie schemes ?

110 DPRE-DRI 110 Extension of such programs to European mobility - Marie Curie Fellowship scheme ? Heterogeneity of scientists career tracks: tenure positions provided by universities vs. research agencies etc… However: the senior positions offered by each country may be viewed as a core status which salary can be maintained by the institution for scientists who wish to work in other countries. As an incentive to mobility, the host institutions might add temporary grants (Interface grants) obtained by the scientist who moves to another country, provided by: hospitals, universities, industry, others… Basis of the program: reciprocity, attractivity … Future prospective : -a more "homogenized" tenure position career track: (salary, social security benefits and taxes, EU-wide health card etc.) - Implication of European Marie Curie programs ?

111 DPRE-DRI 111 Contacts : Inserms web site : Department of French Regional and European Strategic Policies Anne Bisagni, Director : Philippe Arhets, Deputy Director : Cécile Bergouignan, Bilateral cooperation : Human Resources : Researchers task force Anne-Marie Laffaye, School of Inserm, Avenir : Richard Salives, Marie Curie Programme :

112 DPRE-DRI 112 « Le concert », Nicolas de Staël, 1955

113 DPRE-DRI 113


Download ppt "DPRE-DRI 1 Inserm French National Institute of Health and Medical Research Created in 1964 from the National Institute of Hygiene and Hospital Research."

Similar presentations


Ads by Google